BG Medicine Announces Issuance Of Patent Covering Galectin-3 Testing For Cardiac Resynchronization Therapy
Published: Mar 20, 2014
WALTHAM, Mass., March 20, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that on March 18, 2014, the United States Patent and Trademark Office issued patent 8,672,857, titled "Galectin-3 and Cardiac Resynchronization Therapy," to the Company. The patent claims methods for predicting responsiveness to cardiac resynchronization therapy by the measurement of the concentration of the protein galectin-3 in blood.
Help employers find you! Check out all the jobs and post your resume.